Saraf and Partners and Clifford Chance advised TR Capital on the deal. TR Capital executed the acquisition of majority stake in a $150 million Special Purpose...
TR Capital’s Acquisition of Majority Stake in Special Purpose Vehicle from Samara Capital Fund 2
Viatris’ $3.335 Billion Combination of Biosimilars Portfolio with Biocon Biologics
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...